Pfizer company logo (EFE / EPA / OLIVIER HOSLET / ARCHIVE)
The German laboratory BioNTech, a partner of Pfizer, hopes to have the first results of the studies that will determine if the new variant of COVID-19 detected in South Africa is capable of escaping the protection of the vaccine, at the latest “in two weeks,” he said. a spokeswoman.
“We have immediately launched studies on variant B.1.1.529,” which “clearly differs from the variants already known because it has additional mutations in the spike protein” characteristic of the SARS-Cov-2 virus, the spokeswoman explained to the agency of news AFP.
“Pfizer and BioNTech prepared several months ago to adjust their vaccine in less than six weeks and deliver the first doses in 100 days” if a variant proved resistant.
News in development